Cormorant Asset Management, LP 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 3:08 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management, LP | 34,620 4.380% | -21,298 (-38.09%) | Filing |
| 2023-02-14 3:10 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management, LP | 55,918 7.950% | 3,613 (+6.91%) | Filing |
| 2022-02-14 3:10 pm Sale | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management, LP | 52,305 7.500% | -5,714 (-9.85%) | Filing |
| 2021-07-12 4:19 pm Purchase | 2021-07-02 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management, LP | 58,020 8.320% | 58,020 (New Position) | Filing |